MicroRNA-574-5p promotes cell growth of vascular smooth muscle cells in the progression of coronary artery disease - 31/12/17
pages | 6 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Expression of miR-574-5p was elevated in the sera and VSMCs of patients with CA. |
• | Overexpression of miR-574-5p promoted VSMC proliferation. |
• | Overexpression of miR-574-5p inhibited VSMC apoptosis. |
• | MiR-574-5p directly targets ZDHHC14. |
Abstract |
Coronary artery disease (CAD) is caused by atherosclerotic plaque development in the walls of coronary arteries. Aberrant proliferation of vascular smooth muscle cells (VSMCs) promotes atherosclerotic plaque formation, whereas VSMC apoptosis may promote CAD-related inflammation. microRNAs are potential diagnostic biomarkers in cardiovascular disease, especially CAD. Previous reports found that, among patients with CAD, microRNA-574-5p (miR-574-5p) expression was significantly increased and associated with disease severity. However, the specific mechanism by which miR-574-5p affects CAD is unknown. We used quantitative real-time PCR to detect the mRNA expression levels of miR-574-5p in the sera and VSMCs of patients with CAD. We also detected cell proliferation by MTT assay and apoptosis by the Cell Death Detection ELISA-Plus apoptosis assay. We found that miR-574-5p expression was elevated in the sera and VSMCs of patients with CAD. Additionally, miR-574-5p overexpression promoted cell proliferation and inhibited apoptosis in VSMCs. A dual-luciferase reporter assay showed that miR-574-5p directly targets ZDHHC14. In conclusion, our findings indicate that miR-574-5p promotes cell proliferation and inhibits apoptosis by inhibiting ZDHHC14 gene expression, suggesting that miR-574-5p is a CAD-related factor that may serve as a potential molecular target for CAD treatment.
Le texte complet de cet article est disponible en PDF.Keywords : MiR-574-5p, VSMCs, ZDHHC14, Proliferation, Coronary artery disease
Plan
Vol 97
P. 162-167 - janvier 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?